Clinical trials: Recurrent Major Depression
Major Depressive Disorder, Recurrent, Unspecified
Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005
Objectives To evaluate the safety and tolerability of escalating multiple oral doses of LY03005 in healthy subjects. To characterize the pharmacokinetics of escalating multiple oral doses of LY03005.
- Trial name
- NCT02271412
- Testing
- LY03005
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Depressive; Episode, Major, Recurrent Depressive Disorder, Current Episode Moderate
Efficacy of Edupression.Com® in Depressive Patients
The aim of the study is to investigate the efficacy and adherence of the digital self-help programme edupression.com®.
- Conditions
- Depressive; Episode, Major, Recurrent Depressive Disorder, Current Episode Moderate, Recurrent Depressive Disorder, Current Episode Mild
- Trial name
- eFICASY (NCT04839822)
- Testing
- edupression.com®, Health tips, Surveys
- Where
- Austria
- Volunteers
- 250 people
- Sponsor
- Medical University of Vienna
Major Depressive Disorder, Major Depressive Episode
MRS and Medication Response: A Pilot Study
We hope to demonstrate that magnetic resonance spectroscopy can detect brain concentration levels of paroxetine (Paxil) or citalopram (Celexa) or escitalopram (Lexapro) in depressed patients.
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Major Depressive Disorder, Recurrent, Major Depression Mild
- Trial name
- NCT03254342
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Stanford University
Major Depressive Disorder, Major Depressive Disorder, Recurrent
Glutamate Probes in Adolescent Depression
The purpose of this study is to learn if measures of brain chemicals from a brain scan called Magnetic Resonance Imaging and Spectroscopy (MRI/MRS) and brain activity (known as cortical excitability and inhibition) collected by…
- Conditions
- Major Depressive Disorder, Major Depressive Disorder, Recurrent, Major Depressive Disorder, Remitted
- Trial name
- GPII (NCT02307617)
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Depression, Depressive Disorder, Major
Decentering and Relapse/Recurrence in MBCT for Depression in Adults
Objective: "Decentering" is defined as the ability to observe one's thoughts and feelings as temporary, objective events in the mind, and is increasingly regarded as a candidate mechanism in mindfulness-based interventions.
- Conditions
- Depression, Depressive Disorder, Major, Depression in Remission
- Trial name
- NCT05111665
- Testing
- Mindfulness-based Cognitive Therapy (MBCT), Relaxation Group Therapy (RGT), Treatment as usual (TAU)
- Where
- Canada
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Bipolar Disorder, Major Depressive Disorder
Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse
The purpose of this research is to determine if pregnenolone supplement is associated with a reduction in substance use and craving in patients with recurrent major depressive disorder or bipolar disorder and substance…
- Conditions
- Bipolar Disorder, Major Depressive Disorder, Substance Abuse
- Trial name
- NCT00223197
- Testing
- Pregnenolone
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Texas Southwestern Medical Center
Depressive Disorder, Major, Recurrence
Study Evaluating Venlafaxine ER in Recurrent Depression
The purpose of this study is to review the long-term comparative efficacy of venlafaxine ER in achieving and sustaining remission (wellness) in patients with recurrent major depression
- Trial name
- NCT00046020
- Testing
- Venlafaxine ER
- Volunteers
- 1,096 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder, Recurrent
Mechanisms of Mindfulness-Based Cognitive Therapy in the Treatment of Recurrent Major Depressive Disorder
The primary purpose of this study is to investigate neural mechanisms and predictors of treatment outcome in Mindfulness-Based Cognitive Therapy (MBCT) for recurrent Major Depressive Disorder.
- Trial name
- NCT03353493
- Testing
- MBCT, TAU
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- University of Aarhus
Schizophrenia Disorders, Personality Disorders
Recovery in Telling Life Stories
This project tests the Recovery In Telling Life Stories (RETELL) intervention, aimed at supporting personal recovery in people with severe mental illness (SMI).
- Conditions
- Schizophrenia Disorders, Personality Disorders, Obsessive - Compulsive Disorder, Anxiety Disorders
- Trial name
- RETELL (NCT07082777)
- Testing
- Narrative therapy
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- University of Aarhus
Depressive Disorder, Major
Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder
A six week, fixed dose, double-blind, double-dummy, placebo, and active controlled, multicentre trial to evaluate the safety and efficacy of CP-316,311 in outpatients with major depressive disorder.
- Trial name
- NCT00143091
- Testing
- CP-316,311, Sertraline
- Where
- 10 sites in United States, Russia and 1 more
- Volunteers
- 200 people
- Sponsor
- Pfizer
Major Depressive Disorder, Recurrent, Mild, Depressive Disorder, Major
Cortical Excitability and Inhibition in MDD
The purpose of this study is to learn if measures of brain activity are different in children and adolescents with depression who are in different stages of treatment.
- Trial name
- NCT01718730
- Testing
- Transcranial Magnetic Stimulation (TMS), Magnetic Resonance Spectroscopy and Imaging
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mayo Clinic
Major Depressive Disorder
Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder
This primary purpose of this study is to assess the efficacy and safety of Effexor XR in preventing recurrence in Chinese patients with recurrent major depressive disorder (MDD) following a 1-year maintenance treatment after an…
- Trial name
- NCT00878748
- Testing
- Effexor XR, Effexor XR discontinue
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Seasonal Affective Disorder (SAD), Winter Depression
Cognitive-behavioral Therapy vs. Light Therapy for Preventing SAD Recurrence
Major depression is a highly prevalent, chronic, and debilitating mental health problem with significant social cost that poses a tremendous economic burden.
- Conditions
- Seasonal Affective Disorder (SAD), Winter Depression, Major Depressive Disorder, Recurrent, With Seasonal Pattern
- Trial name
- NCT01714050
- Testing
- Cognitive-Behavioral Therapy (CBT), Light Therapy (LT)
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- University of Vermont
Major Depressive Disorder (MDD)
Predictors of Relapse in Major Depressive Disorder (PERFORM-D)
Major depressive disorder (MDD) is a common condition involving recurring periods of depression. One of the major challenges faced by people with MDD is that the episodes of depression tend to recur even after they are…
- Trial name
- PERFORM-D (NCT06746155)
- Where
- 9 sites in Canada
- Volunteers
- 252 people
- Sponsor
- Abraham Nunes
Depressive Symptoms, Major Depressive Disorder, Recurrent, in Remission
The Effects of the Be Mindful Intervention in Previously Depressed Individuals Experiencing Subclinical Symptoms
This study is designed to help individuals cope with their current depressive symptoms by providing them access to a 4-week online Mindfulness-Based Cognitive Therapy: Be Mindful.
- Trial name
- NCT04740879
- Testing
- Be Mindful
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- State University of New York at Buffalo
Schizophrenia, Bipolar Disorder
Peer-delivered and Technology-Assisted Integrated Illness Management and Recovery
Adults with serious mental illness (SMI) are disproportionately affected by medical comorbidity, earlier onset of disease, and 10 to 25 years reduced life expectancy compared to the general population.
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Recurrent, Obesity
- Trial name
- NCT04481737
- Testing
- Peer-delivered and Technology Support Integrated Illness Management and Recovery, Peer support
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Depressive Disorder, Major
A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00208156
- Testing
- Mifepristone
- Where
- 13 sites in United States
- Volunteers
- 87 people
- Sponsor
- Corcept Therapeutics
Depressive Disorder, Major
Mindfulness Based Cognitive Therapy and Antidepressant Medication in Recurrent Depression
The purpose of this study is to investigate the (cost)effectiveness of mindfulness based cognitive therapy (MBCT) compared to that of antidepressant medication, and its combination with regard to the prevention of relapse or…
- Trial name
- NCT00928980
- Testing
- Mindfulness Based Cognitive Therapy, Optimal Medical Care
- Where
- 13 sites in Netherlands
- Volunteers
- 317 people
- Sponsor
- Radboud University Medical Center
Major Depressive Disorder, Major Depressive Disorder, Recurrent
Accelerated Intermittent Theta-Burst Stimulation Ameliorate Major Depressive Disorder by Regulating CAMKII Pathway
Major depressive disorder(MDD) is a complex and heterogeneous mental disorder. Repeated transcranial magnetic stimulation (rTMS), as a non-invasive neuroregulatory technique, has shown a promising function in the treatment of…
- Trial name
- NCT05913960
- Testing
- accelerated intermittent theta burst stimulation, high frequency stimulation
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Healthy, Major Depressive Disorder (MDD)
Neurobiological and Genomic Predictors of Relapse in Depression
The goal of this observational study is to test whether the discontinuation of antidepressant medications for patients with depression can be decided after the normalization of biological parameters.
- Trial name
- MDD (NCT07328373)
- Testing
- Antidepressant Medications
- Where
- Turkey (Türkiye)
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Mehmet Kemal Arikan